| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.0028 | 1 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.003 | 1 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.0027 | 1 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0016 | 1 |